CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 204 enrolled
Drug / intervention
Oliceridinedrug
Likely dose
Oliceridine 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04979247
NCT04979247Phase 4Completed
CompareCT.gov

Intravenous Oliceridine and Opioid-related Complications: VOLITION: A Multicenter Pilot Cohort Study

The Cleveland Clinic·interventional·Posted Jul 28, 2021·Updated May 14, 2026

In Brief

A Phase 4 clinical trial evaluating Oliceridine for Major Surgery. Completed, enrolled 204 participants across 3 sites.

Detailed Summary

The investigator will evaluate the side effects of oliceridine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Surgery
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 28, 2021
Enrollment StartSep 15, 2021
Primary CompletionDec 21, 2023
Study CompletionJan 10, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.9 years ago

Interventions

Oliceridinedrug

Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.